Goldman Sachs Bank Europe SE Synlab AG -- Post-Stabilisation Notice (4465Y)
13 May 2021 - 2:39AM
UK Regulatory
TIDM0A9B
RNS Number : 4465Y
Goldman Sachs Bank Europe SE
12 May 2021
Not for distribution, directly or indirectly, in or into the
United States, Australia, Canada or Japan.
Synlab AG
Post-Stabilisation Notice in accordance with Articles 6(3) and
8(f) of Commission Delegated Regulation (EU) 2016/1052 (Exercise of
Greenshoe Option and End of Stabilisation Period)
12 May 2021
Goldman Sachs Bank Europe SE (contact: Philipp Suess; telephone:
+69 7532 1267), hereby gives notice that the entity undertaking
stabilisation (the "Stabilisation Manager" named below and its
affiliates) undertook stabilisation of the offer of the following
securities in accordance with Article 5(4) and (5) of Regulation
(EU) No 596/2014 (Market Abuse Regulation) and Articles 5 through 8
of Commission Delegated Regulation (EU) 2016/1052:
The securities:
Issuer: Synlab AG
---------------------------------------------------
Securities: Ordinary bearer shares of the Issuer (ISIN:
DE000A2TSL71)
---------------------------------------------------
Stabilisation:
Stabilisation Manager Goldman Sachs Bank Europe SE, Marienturm,
(and central point Taunusanlage 9-10, D-60329 Frankfurt am
within the meaning Main
of Commission Delegated
Regulation (EU)
2016/1052):
---------------------------------------------------
Stabilisation Period: 30 April 2021 until 30 May 2021
---------------------------------------------------
Trading venues Such measures may be taken on the Frankfurt
where stabilisation Stock Exchange (Frankfurter Wertpapierbörse)
were undertaken: from the date when trading in the Shares
is commenced on the regulated market segment
(regulierter Markt) of the Frankfurt Stock
Exchange (Frankfurter Wertpapierbörse),
expected for 30 April 2021, and must be
terminated no later than 30 calendar days
after this date (the "Stabilisation Period").
Stabilisation transactions aim at supporting
the market price of the Shares during the
Stabilisation Period. These measures may
result in the market price of the Shares
being higher than would otherwise have been
the case. Moreover, the market price may
temporarily be at an unsustainable level.
---------------------------------------------------
For each of the date on which stabilisation transactions were
conducted, the price range was as follows:
Execution Date Price Range in EUR Trading Venue
--------------- -------------------- --------------
30-Apr-2021 EUR17.98 - EUR18.00 XETRA
In addition, on 12 May 2021 , the stabilization manager had
partially exercised the greenshoe option granted by the selling
shareholders in connection with over-allotments for 4,590,997
ordinary bearer shares with no-par value of Synlab AG at the offer
price of EUR 18.00 per share.
Disclaimer and Other Notices
This announcement is for information only and does not
constitute an offer or invitation to underwrite, subscribe for or
otherwise acquire or dispose of any securities or investment advice
in any jurisdiction in which such an offer or solicitation is
unlawful, including without limitation, the United States,
Australia, Canada, or Japan. Any failure to comply with these
restrictions may constitute a violation of the securities laws of
such jurisdictions.
This announcement and the information contained herein is not an
offer of securities for sale in, and is not for transmission to or
publication, distribution or release, directly or indirectly, in
the United States of America (including its territories and
possessions, any state of the United States of America and the
District of Columbia) (the "United States"). The securities being
offered have not been and will not be registered under the US
Securities Act of 1933, as amended (the "Securities Act"), or under
any applicable securities laws of any state or other jurisdiction
of the United States and may not be offered, sold, resold,
transferred or delivered, directly or indirectly, in the United
States unless registered under the Securities Act or pursuant to an
exemption from, or in a transaction not subject to, such
registration requirements and in accordance with any applicable
securities laws of any state or other jurisdiction of the United
States. No public offering of the securities discussed herein is
being made in the United States.
Solely for the purpose of the product governance requirements
contained within (a) EU Directive 2014/65/EU of the European
Parliament and of the Council of 15 May 2014 on markets in
financial instruments, as amended ("MiFID II"); (b) Articles 9 and
10 of Commission Delegated Directive (EU) 2017/593 supplementing
MiFID II; and (c) local implementing measures (together, the "MiFID
II Product Governance Requirements"), and disclaiming all and any
liability, whether arising in tort, contract or otherwise, which
any "manufacturer" (for the purposes of the MiFID II Product
Governance Requirements) may otherwise have with respect thereto,
the shares have been subject to a product approval process, which
has determined that the shares are; (i) compatible with an end
target market of retail investors and investors who meet the
criteria of professional clients and eligible counterparties, each
as defined in MiFID II; and (ii) eligible for distribution through
all distribution channels as are permitted by MiFID II (the "Target
Market Assessment"). Notwithstanding the Target Market Assessment,
the price of the shares may decline and investors could lose all or
part of their investment; the shares offer no guaranteed income and
no capital protection; and an investment in the shares is
compatible only with investors who do not need a guaranteed income
or capital protection, who (either alone or in conjunction with an
appropriate financial or other adviser) are capable of evaluating
the merits and risks of such an investment and who have sufficient
resources to be able to bear any losses that may result therefrom.
The Target Market Assessment is without prejudice to the
requirements of any contractual, legal or regulatory selling
restrictions in relation to the offering.
For the avoidance of doubt, the Target Market Assessment does
not constitute (a) an assessment of suitability or appropriateness
for the purposes of MiFID II or (b) a recommendation to any
investor or group of investors to invest in, or purchase, or take
any other action whatsoever with respect to the shares. Each
distributor is responsible for undertaking its own target market
assessment in respect of the shares and determining appropriate
distribution channels.
END
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
STAFZGMKVZNGMZM
(END) Dow Jones Newswires
May 12, 2021 12:39 ET (16:39 GMT)
Synlab (LSE:0A9B)
Historical Stock Chart
From Nov 2024 to Dec 2024
Synlab (LSE:0A9B)
Historical Stock Chart
From Dec 2023 to Dec 2024
